1. Home
  2. OBAI vs LIXT Comparison

OBAI vs LIXT Comparison

Compare OBAI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OBAI

TG-17 Inc. Common Stock

N/A

Current Price

$0.53

Market Cap

25.2M

ML Signal

N/A

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$4.42

Market Cap

26.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBAI
LIXT
Founded
2017
2005
Country
United States
United States
Employees
N/A
3
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
26.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OBAI
LIXT
Price
$0.53
$4.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
30.9K
Earning Date
05-27-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.64
52 Week High
$19.95
$6.09

Technical Indicators

Market Signals
Indicator
OBAI
LIXT
Relative Strength Index (RSI) 21.65 69.83
Support Level $0.44 $3.68
Resistance Level $1.66 $4.96
Average True Range (ATR) 0.10 0.33
MACD 0.10 0.03
Stochastic Oscillator 18.73 96.28

Price Performance

Historical Comparison
OBAI
LIXT

About OBAI TG-17 Inc. Common Stock

Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: